Echoiq Ltd
Research Echoiq Ltd (EIQ) on Bullrun: market cap AUD 351.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEIQ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyAUD
- Market capAUD 351.92M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 351.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.02 | n/a | n/a | n/a |
| FY2024 | AUD 44.50K | -AUD 5.41M | -AUD 4.01M | 100.0% | -0.01 | AUD 2.12M | n/a | AUD 6.77M |
| FY2023 | AUD 107.33K | -AUD 7.80M | -AUD 5.28M | 100.0% | -0.02 | AUD 3.28M | n/a | AUD 7.44M |
| FY2022 | AUD 251.10K | -AUD 5.67M | -AUD 3.18M | 100.0% | -0.02 | AUD 2.41M | n/a | AUD 7.84M |
| FY2021 | AUD 983.18K | -AUD 2.98M | -AUD 1.42M | 100.0% | n/a | AUD 3.81M | n/a | AUD 9.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-14 | AUD 351.92M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Echoiq Ltd
Echo IQ Limited, an artificial intelligence (AI) and medical technology company, engages in the development and application of AI for the cardiac diagnostics sector in Australia. It offers EchoSolv, a machine-learning and AI-based clinical decision support software for use as an adjunct to echocardiography in the assessment of severe aortic stenosis and other cardiovascular conditions. The company has a research collaboration with Mayo Clinic to assess cardiac risk in patients receiving cancer therapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Echoiq Ltd's market cap?
Echoiq Ltd's market capitalization is AUD 351.92M.
What does Echoiq Ltd do?
Echo IQ Limited, an artificial intelligence (AI) and medical technology company, engages in the development and application of AI for the cardiac diagnostics sector in Australia. It offers EchoSolv, a machine-learning and AI-based clinical decision support software for use as an adjunct to echocardiography in the assessment of severe aortic stenosis and other cardiovascular conditions. The company has a research collaboration with Mayo Clinic to assess cardiac risk in patients receiving cancer therapy.